Seer, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
February 29, 2024 at 04:16 pm EST
Share
Seer, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was USD 0.567 million compared to USD 1.72 million a year ago. Revenue was USD 4.44 million compared to USD 4.6 million a year ago. Net loss was USD 17.8 million compared to USD 22.53 million a year ago. Basic loss per share from continuing operations was USD 0.28 compared to USD 0.36 a year ago.
For the full year, sales was USD 4.66 million compared to USD 5.22 million a year ago. Revenue was USD 16.66 million compared to USD 15.49 million a year ago. Net loss was USD 86.28 million compared to USD 92.97 million a year ago. Basic loss per share from continuing operations was USD 1.35 compared to USD 1.49 a year ago.
Seer, Inc. is a life sciences company. The Company is engaged in developing transformative products that open a new gateway to the proteome. Its product, the Proteograph Product Suite (Proteograph), leverages its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access to the proteome. The Proteograph Product Suite is an integrated solution that includes consumables, an automation instrument and software. Its proprietary engineered NPs provide unbiased sampling of intact proteins across the dynamic range of the proteome, capturing molecular information at the peptide-level, including protein variants. It is focused on driving the adoption of the Proteograph by customers in the proteomics and genomics markets. The Proteograph Product Suite is an integrated solution consisting of consumables, an automation instrument, and software to perform biased, deep proteomic analysis at scale in a matter of hours.
SEER, INC. 
